• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

I-Flow Announces New Managed Care Contracts for InfuSystem's Oncology Services

Posted on: Monday, 25 July 2005, 21:00 CDT

I-Flow Corporation (NASDAQ:IFLO) announced today that InfuSystem, a wholly-owned subsidiary of I-Flow Corporation and the nationwide leader in ambulatory infusion management services, signed ten new managed care contracts. These contracts represent more than 10 million lives nationally, and demonstrate managed care's commitment to allowing more patients to have access to the preferred method for outpatient cancer treatment. InfuSystem's services enable oncologists to manage the delivery of chemotherapy for patients while monitoring their progress without the need for the patient to stay in an office or hospital setting.

"Our mission is to make treatment as effective and comfortable as possible for as many cancer patients as possible," said Steve Watkins, president of InfuSystem. "These new contracts not only broaden the coverage for millions, they further validate the outstanding quality of our services and offerings. We believe that we now have contracts for our services covering more than 50 percent of the patients eligible in the United States."

InfuSystem offers the most comprehensive system available for chemotherapy infusion, providing ambulatory infusion pumps and related disposable supplies from a variety of manufacturers while assuming certain administrative functions to achieve overall efficiency and cost-effective clinical outcomes.

About InfuSystem

InfuSystem has nearly 20 years of experience supplying patients with external ambulatory infusion pumps. Our team provides management and support to enhance the lives of our patients and the communities we serve. As a leading company in infusion care, and as one of Medicare's leading durable medical equipment providers, we stay on top of technology to offer the latest in equipment to better serve our patients.

About I-Flow

I-Flow Corporation (www.iflo.com) designs, develops and markets technically advanced drug delivery systems that are redefining the standard of care by providing life-enhancing, cost-effective solutions for pain relief.

Safe Harbor Statement

Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes,""anticipates," or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release, which seek to advise interested parties of the risks, and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food, Drug and Cosmetic Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes; and product availability and acceptance. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.

Source: Business Wire

More News in this Category